NCT05308446 2026-04-21
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT04061980 2026-04-13
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
Providence Health & Services
Phase 2 Active not recruiting
NCT05217446 2026-04-07
SEAMARK
Pfizer
Phase 2 Active not recruiting
NCT04074096 2026-03-25
BEPCOME-MB
UNICANCER
Phase 2 Active not recruiting
NCT05195632 2026-01-07
OCEANII
Pierre Fabre Medicament
Phase 2 Active not recruiting
NCT06578559 2026-01-05
BRICKET
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT02910700 2025-12-17
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04526782 2025-11-18
ENCO-BRAF
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT03235245 2025-08-01
EBIN
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT03839342 2025-02-03
BEAVER
University Health Network, Toronto
Phase 2 Active not recruiting